

Anti-BTLA [HMBT-6B2] VivopureX 25 mg Ab01027-2.3-VXX

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Mouse IgG2a, [Fc Silent™](#), Kappa

Clone Number: HMBT-6B2

Alternative Name(s) of Target: CD272; B and T lymphocyte attenuator; B- and T-lymphocyte attenuator; B and T lymphocyte associated protein; B- and T-lymphocyte-associated protein; BTLA1; FLJ16065; MGC129743

UniProt Accession Number of Target Protein: Q7TSA3

Published Application(s): Blocking, functional assays, immunoblot, IP, WB, FC

Published Species Reactivity: Mouse

Immunogen: This antibody was raised by immunising Armenian hamsters with mouse BTLA:Fc fusion protein.

Specificity: This antibody is specific for B and T lymphocyte attenuator (BTLA), which functions as a negative regulator of T cell activation and proliferation, and attenuates B cell proliferation upon associating with its known ligand, herpes virus entry mediator (HVEM).

Application Notes: This antibody has been used in immunoblot analyses to confirm that B and T lymphocyte attenuator (BTLA) regulates T cell activation through interaction with herpesvirus entry mediator (HVEM) (Sedy et al, 2005), as well as in FACS and yeast display technology to demonstrate that BTLA exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T Cells (Hurchla et al, 2005). In a mouse conjunctivitis model, treatment with this antibody during the induction phase has been shown to decrease B-cell population, upregulate Th2 cytokine production and increase the conjunctival eosinophile numbers (Ishida et al, 2012). However, treatment with this antibody during the effector phase does not affect the development of experimental conjunctivitis (Ishida et al, 2012).

Antibody First Published in: Waka Ishida et al. B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2012 Feb;250(2):289-95. [PMID:21779950](#)

Note on publication: Describe the use of this antibody, together with the anti-HVEM antibody, to investigate the roles that B and T lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM)

play in the development of antigen-induced experimental conjunctivitis (EC).

Product Form

Size: 25 mg VivopureX products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. These antibodies are chimerized to have an Fc domain matching their target species to reduce immunogenicity and give you the optimal effector function for your experiment. As a result VivopureX products are the ideal choice for in vivo research applications.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions.

Concentration: ≥ 1 mg (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.